Research map: Therapeutic drift or formulation drift: avoiding misconceptions about rifaximin and antimicrobial resistance in cirrhosis

Back to the article

Papers in this map

  1. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy · Sara Montagnese · 2022 · 442 citations · Cited by this paper
  2. Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial · 2026 · Related
  3. Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis · Amirhossein Shamsaddini · 2021 · 73 citations · Cited by this paper
  4. Ethnicity, diversity, and inclusion in gastroenterology: from representation to system performance · 2026 · Related
  5. Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017 · Carmelo Scarpignato · 2018 · 57 citations · Cited by this paper
  6. Cyclic exclusive enteral nutrition in paediatric Crohn's disease – Authors’ reply · 2026 · Related
  7. Lack of Association Between Rifaximin and Drug-resistant Infections: A global multicenter inpatient cirrhosis cohort. · Jasmohan Singh Bajaj · 2025 · 5 citations · Cited by this paper
  8. Rome V: refining the language of gut–brain disorders · 2026 · Related
  9. Rifaximin in cirrhosis: when therapeutic drift meets antimicrobial stewardship · Rajiv Jalan · 2026 · 2 citations · Cited by this paper
  10. The spectrum of steatotic liver disease in the USA – Authors’ reply · 2026 · Related
  11. Drugging the undruggable in pancreatic cancer · 2026 · Related
  12. Pathophysiology of irritable bowel syndrome · 2026 · Related
  13. Translating the gut microbiome: where are we? · 2026 · Related

Source: OpenAlex (CC0)